Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21236222 | 0.87 | ALDH1A1 (0.36) | ALDH1A1MAPK1KMT2AMEN1TDP1 | |
| SCHEMBL22023973 | 0.84 | KMT2A (0.40) | ALDH1A1MAPK1KMT2AMEN1TDP1 | |
| SCHEMBL19040901 | 0.81 | KMT2A (0.41) | ALDH1A1MAPK1KMT2AMEN1TDP1 | |
| SCHEMBL1104678 | 0.77 | KMT2A (0.46) | ALDH1A1MAPK1KMT2AMEN1TDP1 | |
| SCHEMBL6002955 | 0.74 | KMT2A (0.44) | ALDH1A1MAPK1KMT2AMEN1TDP1 | |
| SCHEMBL20047543 | 0.71 | — | — | |
| SCHEMBL20857327 | 0.70 | TLR8 (0.39) | ALDH1A1KMT2AMEN1TDP1GAA | |
| SCHEMBL23502449 | 0.70 | NR1H2 (0.33) | GAAMAPT | |
| SCHEMBL7091614 | 0.70 | CA2 (0.50) | ALDH1A1KMT2AMEN1TDP1POLB | |
| SCHEMBL20780688 | 0.67 | MAPK1 (0.44) | ALDH1A1MAPK1KMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198206-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198206-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | ALDH1A1 1326/4885MAPK1 1197/4885KMT2A 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.